The global healthcare ecosystem in 2026 is leading to a strong recovery in clinical research, with global pharma R&D investment topping $250 billion and the clinical research organization (CRO) market rising to $72 billion at roughly a 9% annual pace.
As biopharma companies move capital into complex biologic pipelines, AI-powered trial improvement, and practical data analysis, outsourcing fervor grows
For industry leaders such as IQVIA Holdings Inc. (NYSE:IQV), this macro environment provides structural tailwinds, allowing scaled global operators to grab high-margin clinical trial operations and lock in multi-year backlog visibility. Record $3.15 Billion Bookings IQVIA Holdings Inc. (NYSE:IQV) proved the extent of its operational recovery in its second-quarter 2026 results on July 29, exceeding the upper end of its internal guidance across all main financial indicators and driving an 8.8% pre-market share jump. Total revenue was $4.368 billion, increasing 8.7% year-over-year, exceeding analyst estimates, while adjusted diluted earnings per share increased 12.1% year-over-year to $3.15, beating consensus projections of $3.02 to $3.06 by a significant margin.
At the same time, adjusted EBITDA increased by 9.2% to $994 million, sustaining a 22.8% margin. While headline earnings and revenue were solid, the true source of the market’s optimism was an impressive spike in clinical bookings. IQVIA’s core Research & Development Solutions division recorded record net new bookings of $3.15 billion, up 19% year-over-year, with a strong book-to-bill ratio of 1.22x.